Clinical trial readout dates for Liquidia Corporation, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is February 2027.
| Phase 2 LIQ861 (treprostinil) inhalation powder Raynaud's Phenomenon Secondary to Systemic Sclerosis · NCT07748000 | February 2027 Not Yet Recruiting |
| Phase 3 L606 Pulmonary Hypertension Due to Lung Disease (Disorder) · NCT07285655 | July 2029 Recruiting |
Liquidia Corporation reported $396M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-10). Its net loss for that quarter was $236M; at that rate the cash would last about 2 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Other Events — often topline trial data | 2026-11-10 |